Found: 9
Select item for more details and to access through your institution.
NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 139, doi. 10.1007/s40273-020-00990-8
- By:
- Publication type:
- Article
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 257, doi. 10.1007/s40273-020-00978-4
- By:
- Publication type:
- Article
Modifying NICE's Approach to Equity Weighting.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 147, doi. 10.1007/s40273-020-00988-2
- By:
- Publication type:
- Article
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review.
- Published in:
- 2021
- By:
- Publication type:
- research
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
- Published in:
- 2021
- By:
- Publication type:
- journal article
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 181, doi. 10.1007/s40273-020-00965-9
- By:
- Publication type:
- Article
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 243, doi. 10.1007/s40273-020-00964-w
- By:
- Publication type:
- Article